In fibroblast culture studies, GHK-Cu has been shown to stimulate production of both type I and type III collagen, the two primary collagens involved in wound healing
Data limitations: No completed human efficacy trial exists for any indication, and the literatures short observation windows mean long-term safety in either animals or humans remains unestablished
Histone modifications, DNA methylation, and non-coding RNA molecules are some of these alterations that have the ability to either stimulate or inhibit gene expression
Potential benefits of using GLP-1 receptor agonists after gastric sleeve surgery include: Enhanced weight loss : Observational studies suggest post-bariatric patients using GLP-1 receptor agonists may achieve additional weight reduction, typically around 510% of body weight, though individual responses vary considerably Improved glycaemic control : Particularly beneficial for patients with type 2 diabetes or prediabetes, as GLP-1 agonists enhance insulin secretion and reduce blood glucose levels Reduced appetite : These medications can help patients who struggle with persistent hunger despite surgical intervention Cardiovascular benefits : Semaglutide has demonstrated cardiovascular risk reduction in people with established cardiovascular disease, which may benefit eligible post-bariatric patients with this specific risk profile Maintenance of weight loss : May help prevent weight regain during the critical maintenance phase Potential risks and considerations include: Gastrointestinal side effects : Nausea, vomiting, diarrhoea, and constipation are common, particularly during dose escalation
Not all syringes have the same unit markings
